Actively Recruiting
Video-oculography and Parkinson's Disease
Led by Association de Recherche Bibliographique pour les Neurosciences · Updated on 2025-10-01
30
Participants Needed
1
Research Sites
547 weeks
Total Duration
On this page
Sponsors
A
Association de Recherche Bibliographique pour les Neurosciences
Lead Sponsor
C
Centre Hospitalier Princesse Grace
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015): * the evolution of oculomotricity markers over time. * the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and oculomotricity evaluation, over a follow-up period of 7 years. * the impact of antiparkinsonian drugs on the evolution of oculomotricity assessment by video-oculography. * the value of oculomotricity assessment by video-oculography as an evolutionary marker of the disease.
CONDITIONS
Official Title
Video-oculography and Parkinson's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female
- Clinically diagnosed idiopathic Parkinson's Disease
- Brain MRI done within 12 months before inclusion
- Cerebral DaTSCAN or PET with F-DOPA done before inclusion confirming presynaptic dopaminergic denervation
- Hoehn & Yahr score between 1 and 3
- Normal clinical eye movement exam (slight smooth pursuit impairment allowed)
- No or minor neuro-cognitive disorders according to DSM5
- Able to read and speak French sufficiently
- Covered by a health insurance system
- Signed written informed consent
- Presence of a caregiver
You will not qualify if you...
- Significant psychiatric comorbidity except anxiety or mild/moderate depression
- Significant neurological comorbidity
- Brain MRI showing significant cerebrovascular pathology beyond Fazekas I or another brain disease including stroke
- Major cognitive impairment
- Presence of red flags indicating another degenerative extrapyramidal disorder such as cerebellar syndrome, vertical eye movement disorders, motor symptoms limited to lower limbs, symmetrical parkinsonism, early dystonia, behavioral variant frontotemporal dementia, progressive aphasia or apraxia, moderate/severe postural instability or early falls, early bulbar dysfunction, ventilatory dysfunction, severe dysautonomia, DOPA resistance, or neuroleptic treatment
- Normal myocardial scintigraphy with MIBG if performed
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital
Monaco, Monaco, 98000
Actively Recruiting
Research Team
S
Solange HESSE
CONTACT
K
Kévin POLET
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here